TSX Venture Exchange: MDX
Early detection points to reduction of costs and patient wait
times for Canadians
MISSISSAUGA, ON, Jan. 9, 2017 /CNW/ - MedX Health Corp.
("MedX") (TSX-V: MDX) announced today that it has entered into a
Memorandum of Understanding with Calian Health's Primacy Management
Inc. ("Primacy"), to conduct a pilot program with MedX's unique
skin assessment screening solution in select Primacy clinics.
Primacy is the largest medical clinic management company in
Canada with more than 800
physicians practicing at more than 140 clinics located in Loblaw
stores (including Real Canadian Superstore®,
Zehrs®, Loblaws® and No Frills®)
across Canada. Primacy clinics
collectively serve over 6 million patients a year.
According to the Skin Cancer Foundation of Canada, 80,000 skin cancers are diagnosed in
Canada each year, more than 5,000
of which are melanoma, the deadliest form of skin cancer. There are
more new cases of skin cancer annually than those of breast,
prostate, lung and colon cancers combined. Despite this, only about
10% of Canadians have their moles and lesions screened on a regular
basis.
"Regular screening is key to early detection and reducing the
cost and health impact of skin cancer," said Rob von der Porten, President and CEO of MedX.
"Making screening easily available and having these images assessed
remotely by dermatologists using the Ontario Telemedicine Network
promises to fill a gap in assessment, while leveraging
dermatologists' time and skills," he added. Mr. von der Porten noted that when skin cancers are
caught early, they are treatable at a low cost to the health care
system. If not caught until later stages the prognosis deteriorates
and the treatment cost escalates.
Primacy believes that by leveraging their clinic network to
provide ease of access to dermatological triaging, current wait
times for patients could be significantly reduced. "Upon
successful completion of the pilot, we are planning a broader
roll-out of this service to give even more Canadians access to
early screening, which we hope will dramatically improve skin
cancer's impact," said Melanie
Holek, General Manager of Primacy.
"We are delighted to have Primacy as our channel partner," said
Mr. von der Porten. "We believe
their in-depth knowledge and experience in providing solutions to
health problems facing Canadians is superior and
wide-reaching."
The pilot project allows individuals with concerns over
potential skin abnormalities to be seen by physicians at select
Primacy locations. If a mole or lesion appears suspicious, the
person will have the option of being scanned using MedX's proven
Siascopy technology, and the scan will be forwarded to a
dermatologist who will complete an assessment within 72 hours. This
technology could dramatically reduce patient wait times to have a
suspicious mole or lesion, diagnosed by a dermatologist and allow
potentially life-threatening skin cancers to get expedited
treatment.
"MedX's SIAscopy technology is currently being used in more than
200 pharmacy and clinic locations in Norway, Sweden and the UK in similar networked
solutions as well as in hundreds of stand-alone applications
internationally with physicians, so it is especially rewarding to
be launching in Canada," noted Mr.
von der Porten.
About MedX
MedX, headquartered in Mississauga, Ontario, is a leading medical
device company focused on skin cancer with its SIAscopy technology.
This technology is imbedded in its products SIAMETRICS™, SIMSYS™,
and MoleMate™, which MedX manufactures in its ISO 13485 certified
facility. SIAMETRICS™, SIMSYS™, and MoleMate™ include
hand-held devices that use patented technology utilizing light and
its remittance to view up to 2 mm beneath suspicious moles and
lesions in a pain free, non-invasive manner, with its software then
creating real-time images for physicians and dermatologists to
evaluate all types of moles or lesions within seconds. The devices
are sold to physicians and clinics, as well as being deployed in
pharmacies and remote clinics from where the images are sent to
dermatologists who perform a diagnosis. These products are Health
Canada, FDA (US), ARTG and CE approved for use in Canada, the US, Australia, the European Union and
Turkey. SIAMETRICS™ is a unique product used in a specialized
market for research into the clinical effectiveness of medical
treatments of certain skin conditions. MedX also designs,
manufactures and distributes quality laser and light therapy
technologies for use in numerous medical settings, approved in
major jurisdictions, to provide drug free and non-invasive
treatment of tissue damage and pain. For more information and a
complete profile of MedX and its products visit
www.medxhealth.com.
About Primacy Management Inc., a Calian Group
Company
Primacy is the largest medical
clinic management company in Canada with more than 800 physicians
practicing at more than 140 clinics located in Loblaw stores
(including Real Canadian Superstore®, Zehrs®,
Loblaws® and No Frills®) across Canada. Primacy clinics collectively serve
over 6 million patients a year.
About Calian Health
Calian Health is one of
Canada's largest national health
services organizations with over 10 years of experience in the
management of healthcare professionals and health programs, as well
as the operation and management of primary care and occupational
health clinics. With a network of over 1,500 healthcare
professionals, Calian supports over six million patient visits per
year at over 180 clinic locations across Canada.
DISCLAIMER
This press release does not constitute an
offer of any securities for sale. This press release contains
certain forward-looking statements within the meaning of applicable
Canadian securities legislation. These forward-looking statements
involve certain risks and uncertainties that could cause actual
results to differ, including, without limitation, the company's
limited operating history and history of losses, the inability to
successfully obtain further funding, the inability to raise capital
on terms acceptable to the company, the inability to compete
effectively in the marketplace, the inability to complete the
proposed acquisition and such other risks that could cause the
actual results to differ materially from those contained in the
company's projections or forward-looking statements. All
forward looking statements in this press release are based on
information available to the company as of the date hereof, and the
company undertakes no obligation to update forward-looking
statements to reflect events or circumstances occurring after the
date of this press release.
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of
this press release.
SOURCE MedX Health Corp.